Acorda Therapeutics, Inc. (ACOR) to Release Quarterly Earnings on Wednesday
Acorda Therapeutics, Inc. (NASDAQ:ACOR) is scheduled to release its earnings data before the market opens on Wednesday, July 26th. Analysts expect Acorda Therapeutics to post earnings of $0.49 per share for the quarter.
Acorda Therapeutics (NASDAQ:ACOR) last released its quarterly earnings results on Thursday, April 27th. The biopharmaceutical company reported ($0.08) earnings per share for the quarter, beating the consensus estimate of ($0.16) by $0.08. Acorda Therapeutics had a negative return on equity of 5.94% and a negative net margin of 10.13%. The firm had revenue of $119.39 million for the quarter, compared to analysts’ expectations of $127.34 million. During the same quarter last year, the firm posted $0.28 EPS. The company’s revenue was up 3.0% compared to the same quarter last year. On average, analysts expect Acorda Therapeutics to post $1.97 EPS for the current fiscal year and $0.88 EPS for the next fiscal year.
Shares of Acorda Therapeutics, Inc. (ACOR) opened at 20.10 on Wednesday. The stock’s market cap is $939.84 million. The firm has a 50 day moving average price of $18.20 and a 200 day moving average price of $20.23. Acorda Therapeutics, Inc. has a 12-month low of $13.60 and a 12-month high of $33.00.
A number of research firms have recently weighed in on ACOR. BidaskClub lowered Acorda Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Thursday, July 13th. Jefferies Group LLC began coverage on Acorda Therapeutics in a research note on Monday, July 10th. They issued a “hold” rating and a $22.00 price objective for the company. J P Morgan Chase & Co set a $24.00 price objective on Acorda Therapeutics and gave the stock a “hold” rating in a research note on Tuesday, June 6th. Cowen and Company reaffirmed an “outperform” rating and issued a $35.00 price objective on shares of Acorda Therapeutics in a research note on Wednesday, June 7th. Finally, TheStreet lowered Acorda Therapeutics from a “c-” rating to a “d+” rating in a research note on Monday, April 24th. Seven research analysts have rated the stock with a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average target price of $25.26.
In related news, insider Ron Cohen acquired 20,000 shares of the firm’s stock in a transaction on Friday, June 16th. The shares were acquired at an average cost of $16.95 per share, for a total transaction of $339,000.00. Following the completion of the transaction, the insider now directly owns 511,648 shares in the company, valued at approximately $8,672,433.60. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, insider Andrew A. Hindman sold 7,704 shares of the company’s stock in a transaction that occurred on Monday, May 15th. The shares were sold at an average price of $15.75, for a total value of $121,338.00. Following the sale, the insider now owns 46,123 shares in the company, valued at $726,437.25. The disclosure for this sale can be found here. 7.90% of the stock is currently owned by insiders.
About Acorda Therapeutics
Acorda Therapeutics, Inc is a biopharmaceutical company. The Company focuses on developing therapies that restore function and improve the lives of people with neurological disorders. As of December 31, 2016, the Company marketed three United States Food and Drug Administration (FDA)-approved therapies, including Ampyra (dalfampridine) Extended Release Tablets, 10 milligram (mg), a treatment to improve walking in patients with multiple sclerosis (MS).
Receive News & Ratings for Acorda Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acorda Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.